Evaluation of efficacy of transurethral plasmakinetic resection of prostate of benign prostatic hyperplasia
JIANG Hong-tao1 QIN Guo-qing1 LIU Luo-gen2 ZHANG Yun-sheng2 ZHOU Ming-shu3 ZHANG Hong3 WANG Yi1▲
1.Department of Urology，the Second Affiliated Hospital，University of South China,Hengyang 421001，China;
2.Clinical Research Institute，the Second Affiliated Hospital，University of South China,Hengyang 421001，China;
3.The College of Clinical Medicine，University of South China,Hengyang 421001，China
Abstract：ObjectiveTo investigate the effects of transurethral resection of prostate on intraoperative blood loss，therapeutic effect and postoperative complications of patients with benign prostatic hyperplasia(BPH).MethodsThe clinical data of 80 cases of patients with benign prostatic hyperplasia in our hospital from January 2015 to January 2017 were retrospectively analyzed，these patients were divided into TURP group(study group，n=40)and open surgical gland resection group（control group，n=40)two groups according to the treatment methods，the operation time，intraoperative blood loss，indwelling catheter time，IPSS scores，Qmax，RUV，QOL scores，therapeutic effects，postoperative complications of the two groups were statistically analyzed.ResultsThe operation time，indwelling catheter time of the study group were significantly shorter(P＜0.05)，the intraoperative blood loss was significantly less(P＜0.05)，the IPSS score，RUV were significantly lower(P＜0.05)，the Qmax，QOL score were significantly higher(P＜0.05)，the total treatment efficiency [92.5%(37/40)]was significantly higher than that of the control group[75.0%(30/40)](P＜0.05)，the postoperative complications rate[17.5%(7/40)]was significantly lower than that of the control group[35.0%(14/40)](P＜0.05).ConclusionTransurethral resection of prostate is more effective in reducing the intraoperative blood loss，improving the therapeutic effect，reduce the postoperative complications of patients with benign prostatic hyperplasia than open surgical gland resection.
Rajnish K，Pankaj C，Priyanka M，et al.Synthesis，biological evaluation and in silico studies of novel 5α-aza-bhomo-3，5-secosteroids as potential 5-reductase inhibitors[J].Drug Des Devel Ther，2016，13（9）：869-878.
[15]
Osama E，Naira M，Joanna S，et al.Differentiating transition zone cancers from benign prostatic hyperplasia by quantitative multiparametric magnetic resonance imaging[J].J Comput Assist Tomogr，2016，40（2）：218-224.
[16]
Marisa C，Araceli SM，Mariana G，et al.Recent advances in drug design and drug discovery for androgen-dependent diseases[J].Curr Med Chem，2016，23（8）：792-815.
[17]
Luisella P，Petros S，Pietro C，et al.Current pharmacological treatment for male LUTS due to BPH：dutasteride or finasteride?[J].Curr Drug Targets，2015，16（11）：1165-1171.
[18]
Claus GR，Igor OP，Erik PMR，et al.Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment?A post hoc analysis of data from the 2-year CONDUCT study[J].World J Urol，2017，5（3）：421-427.
[19]
Petros S，Stavros G.The impact of combination therapy with a-blockers and 5ARIs on the progression of BPH[J].Curr Drug Targets，2015，16（11）：1172-1179.
[20]
Sonal G，Gopal G，Sharma V.L.Evolving novel chemical entities for management of benign prostatic hyperplasia[J].Mini Rev Med Chem，2017，17（7）：593-602.（收稿日期：2017-04-19本文编辑：崔建中）
京公网安备 11010502046607号